Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
GAITHERSBURG, Md., Oct. 31, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter financial and operating results following the close of U.S. financial markets on Tuesday, November 7, 2017.
Conference call details are as follows:
| Date: | Tuesday, November 7, 2017 |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 2479419 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starts at 7:30 p.m. ET, Nov. 7, 2017 until 7:30 p.m. ET, Nov. 14, 2017 |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 2479419 |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until February 7, 2018 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Russo Partners, LLC
David Schull
Maggie Beller
[email protected]
[email protected]
212-845-4271
